Halle Moore, MD

Halle Moore, MD, an oncologist in the department of hematology and medical oncology at the Cleveland Clinic, discusses the results of the IBIS-II DCIS trial (NCT00072462) of anastrozole versus tamoxifen after 12 years of follow-up for postmenopausal patients with locally excised ductal carcinoma in situ (DCIS).

The original presentation of this trial did not show a difference between these 2 agents but demonstrated the noninferiority of anastrozole when compared with tamoxifen, according to Moore. There were no significant variances in the risk of recurrence of these patients in the updated analysis, with about a 1% difference. For invasive recurrence or more rarely death from breast cancer in these patients with noninvasive breast cancer, there were no changes in the outcomes for these 2 drugs. The main difference was for the toxicity profiles.

Moore says that this trial shows there are options for patients with DCIS. Patients with severe osteoporosis with concerns of muscular-skeletal symptoms may be prescribed tamoxifen as a risk-reducing agent. On the other hand, patients at risk for blood clots or uterine cancer may receive an aromatase inhibitor. Both are reasonable options to consider in this setting, she thinks.

Videos

Halle Moore, MD, discusses the results of the IBIS-II DCIS trial of anastrozole versus tamoxifen after 12 years of follow-up for postmenopausal patients with locally excised ductal carcinoma in situ.

Long-Term Results Show Comparable Efficacy for Anastrozole and Tamoxifen

Halle Moore, MD, medical oncologist, Cleveland Clinic, discusses a

phase III trial presented at the 2014 ASCO Annual Meeting

that looked at reducing the risk of premature ovarian failure with LHRH analog administration with chemotherapy in women with breast cancer.

The randomized phase III POEMS study looked at whether suppressing ovarian function during adjuvant or neoadjuvant chemotherapy could reduce the risk for long term ovarian failure in premenopausal women with ER-negative breast cancer.

Patients were randomized to receive standard cyclophosphamide-containing chemotherapy with or without monthly LHRH analog goserelin.

There was a significant reduction (about 70%) in the ovarian failure rate observed in the group treated with goserelin.

At 2 years, women who received goserelin had better preserved ovarian function.

There was a higher rate of achieving pregnancy and having successful births among women who received goserelin. There was no evidence that goserelin increased the risk of miscarriage, need for elective termination, or other adverse pregnancy events.

The goserelin group had an improved disease-free survival as well as overall survival compared with the control group.

View more from the 2014 ASCO Annual Meeting

Halle Moore, MD, discusses a phase III trial that looked at reducing the risk of premature ovarian failure with LHRH analog administration with chemotherapy in women with breast cancer.

Halle Moore, MD | Authors

Articles

Long-Term Results Show Comparable Efficacy for Anastrozole and Tamoxifen

Reducing the Risk of Premature Ovarian Failure With LHRH Analog Administration With Chemotherapy in Breast Cancer